As RFK Jr. winds down mRNA vaccine research, experts warn America may lose its edge in vaccine development, putting public health at risk and ceding ground to adversaries like China.
In a surprising move, the Trump administration, under Robert F. Kennedy Jr., has canceled over $500 million in funding for mRNA vaccine development, raising alarms about America's future public health preparedness. Experts warn this could lead to dangerous vulnerabilities against infectious diseases.
NIH Director Jay Bhattacharya reveals that millions in mRNA research contracts were canceled due to public distrust. He argues that without credibility, mRNA technology can't serve its health mission.
The NIH's Jay Bhattacharya argues that public distrust led to the cancellation of mRNA vaccine contracts. This statement contrasts with Health Secretary Kennedy's claims about vaccine safety and efficacy.
Discover how researchers at IBM and Moderna have leveraged quantum computing to predict the complex protein structure of mRNA, marking a significant advancement in vaccine technology.
The U.S. government has canceled a crucial $770 million contract with Moderna for an avian flu vaccine, risking public health as pandemics prove to be a costly threat. Experts warn of the implications of prioritizing military spending over health security.
In a surprising move, the HHS has terminated a $590 million contract with Moderna for H5 avian influenza vaccine development, raising alarms among health experts amidst rising H5N1 threats.
In a surprising move, the Department of Health and Human Services has withdrawn millions in funding for Moderna's bird flu vaccine development, raising concerns about the nation's pandemic preparedness amid ongoing tensions over vaccine safety.
Vaccine experts are divided over the Trump administration's Generation Gold Standard project aimed at creating a universal flu vaccine. While some praise the initiative, others question its outdated methods and hefty price tag.
The announcement of a $500 million NIH project to develop a vaccine platform using outdated technology has divided experts, sparking concerns about the future of pandemic preparedness and funding priorities.
